Jefferies Initiates Inozyme Pharma(INZY.US) With Buy Rating, Announces Target Price $17
Inozyme Pharma: A Buy Rating With Multi-Billion Dollar Market Potential and Upcoming Catalysts
Inozyme Pharma Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
Inozyme Pharma: A Buy Rating Backed by Clinical Trials and Market Potential
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Glaukos (GKOS)
Inozyme Pharma Analyst Ratings
Inozyme Pharma Analyst Ratings
Buy Rating Affirmed for Inozyme Pharma Amid Promising Drug Developments and Strong Revenue Projections
Inozyme Pharma Analyst Ratings
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Inozyme Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)
Buy Rating on Inozyme Pharma Supported by Advancements in Lead Program and Promising Market Opportunities
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
Inozyme Pharma Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)